GAITHERSBURG, Md., March 04, 2025--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today an indication expansion for its ...

GeneDx’s industry leading exome and genome empower clinicians with comprehensive genetic insights to uncover genetic factors contributing to CP. The testing provides valuable information that ...

This strategic indication expansion underscores the importance of improving access to exome and genome testing for patients with CP to shorten the diagnostic odyssey and accelerate the path to ...

Through the combination of GeneDx’s industry leading proprietary dataset, publicly available data, and the power of AI, Multiscore prioritizes genes with positive findings in exome and genome ...

Through the combination of GeneDx’s industry leading proprietary dataset, publicly available data, and the power of AI, Multiscore prioritizes genes in exome and genome sequences by ranking them ...

GeneDx Price Performance NASDAQ:WGS opened at $104.39 on Monday. The firm has a market capitalization of $2.93 billion, a price-to-earnings ratio of -53.26 and a beta of 1.91. GeneDx Holdings Corp ...

GeneDx (NASDAQ:WGS – Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.04 by $0.66.